SGMO240719C500
- 0.10
- 0.000.00%
Sangamo Therapeutics Newsroom
The Market Doesn't Like What It Sees From Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues Yet As Shares Tumble 30%
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. (NASDAQ:SGMO) share price has dived 30% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous t
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive Into Financials and Strategic Highlights
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings
Sangamo Therapeutics | 10-Q: Quarterly report
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
04:03 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
Express News | Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Sangamo Therapeutics 1Q Rev $481,000 >SGMO
Express News | Sangamo Therapeutics Q1 Net Income USD -49.089 Million
Express News | Sangamo Therapeutics Q1 Operating Income USD -51.526 Million
Express News | Sangamo Therapeutics Q1 Operating Expenses USD 52 Million
Express News | Sangamo Therapeutics Q1 Revenue USD 481 Thousand Vs. Ibes Estimate USD 6.65 Million
Express News | Sangamo Therapeutics Presents Modular Integrase Technology Engineered To Enable Large-Scale Genome Editing